Trials / Completed
CompletedNCT00234533
Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
Phase IIIB, International, Single Group, Open Study to Define an Optimal Monitoring of IGF-1 in Children Treated With NutropinAq, Using a Novel Capillary Blood Collection Method
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 251 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to establish an optimal monitoring regimen in NutropinAq treated children, using newly developed capillary blood spot IGF-1 measurement technology.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Somatropin (rDNA origin) | Daily subcutaneous injections, 0,025 - 0,05 mg/kg/day for 6 months. |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2005-10-07
- Last updated
- 2019-12-09
- Results posted
- 2018-08-09
Locations
45 sites across 14 countries: Belgium, Czechia, Denmark, Finland, France, Germany, Greece, Italy, Romania, Russia, Slovakia, Spain, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00234533. Inclusion in this directory is not an endorsement.